Alembic Pharmaceuticals has informed that their Associate Company, Rhizen Pharmaceuticals S.A. (Rhizen) has released a Press Release announcing that the USFDA has granted Orphan-Drug Designation for Tenalisib (RP6530). Couple of weeks back also the company had informed that USFDA has granted Fast Track Designation for Tenalisib (RP6530) to Rhizen.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1676.05 |
| Dr. Reddys Lab | 1237.50 |
| Cipla | 1239.40 |
| Zydus Lifesciences | 942.20 |
| Lupin | 2327.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: